Integer Holdings Co. (NYSE:ITGR) Stock Holdings Lessened by Edgestream Partners L.P.

Edgestream Partners L.P. cut its position in Integer Holdings Co. (NYSE:ITGR) by 46.5% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 11,910 shares of the medical equipment provider’s stock after selling 10,354 shares during the quarter. Edgestream Partners L.P.’s holdings in Integer were worth $1,578,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Mather Group LLC. lifted its position in Integer by 304.3% in the 4th quarter. Mather Group LLC. now owns 190 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 143 shares during the last quarter. Huntington National Bank lifted its position in Integer by 8,933.3% in the 3rd quarter. Huntington National Bank now owns 271 shares of the medical equipment provider’s stock valued at $35,000 after purchasing an additional 268 shares during the last quarter. R Squared Ltd bought a new stake in Integer in the 4th quarter valued at about $44,000. Versant Capital Management Inc lifted its position in Integer by 98.4% in the 4th quarter. Versant Capital Management Inc now owns 369 shares of the medical equipment provider’s stock valued at $49,000 after purchasing an additional 183 shares during the last quarter. Finally, Principal Securities Inc. lifted its position in Integer by 31.2% in the 4th quarter. Principal Securities Inc. now owns 639 shares of the medical equipment provider’s stock valued at $85,000 after purchasing an additional 152 shares during the last quarter. 99.29% of the stock is currently owned by institutional investors.

Integer Stock Down 1.2 %

NYSE ITGR opened at $120.55 on Tuesday. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.95 and a quick ratio of 2.09. The company’s 50 day simple moving average is $135.21 and its 200 day simple moving average is $132.99. Integer Holdings Co. has a 12 month low of $107.11 and a 12 month high of $146.36. The company has a market capitalization of $4.05 billion, a P/E ratio of 35.88, a PEG ratio of 1.72 and a beta of 1.24.

Integer (NYSE:ITGR) last released its earnings results on Thursday, February 20th. The medical equipment provider reported $1.43 EPS for the quarter, missing analysts’ consensus estimates of $1.46 by ($0.03). Integer had a return on equity of 11.65% and a net margin of 6.92%. The business had revenue of $449.50 million during the quarter, compared to the consensus estimate of $446.28 million. Equities research analysts expect that Integer Holdings Co. will post 6.01 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently weighed in on ITGR shares. Citigroup lifted their price objective on shares of Integer from $130.00 to $145.00 and gave the company a “neutral” rating in a research report on Wednesday, December 11th. Benchmark raised their target price on shares of Integer from $140.00 to $150.00 and gave the company a “buy” rating in a research note on Friday, February 21st. Wells Fargo & Company reissued an “overweight” rating and set a $160.00 target price on shares of Integer in a research note on Tuesday, December 3rd. Truist Financial raised their target price on shares of Integer from $147.00 to $163.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. Finally, KeyCorp raised their target price on shares of Integer from $144.00 to $154.00 and gave the company an “overweight” rating in a research note on Friday, January 24th. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, Integer currently has an average rating of “Moderate Buy” and a consensus price target of $147.67.

Integer Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.